Hinckley Greg K 4

What Happened
Greg K. Hinckley, a director of Bio‑Rad Laboratories (BIO), had restricted stock units vest and executed derivative conversions on April 21, 2026. The filing shows 369 shares were acquired as the vesting of restricted stock units (reported at $0.00). On the same date Hinckley recorded an exercise/conversion of 407 derivative shares that were acquired and also recorded as disposed the same day (both at $0.00). The reported dollar price for these entries is $0.00, meaning no cash price was recorded on the Form 4.

Key Details

• Transaction date: April 21, 2026; Form 4 filed April 23, 2026 (appears timely — within two business days).
• Reported transactions:
  • A (Award/Grant): 369 shares acquired (RSU vesting) at $0.00.
  • M (Exercise/Conversion): 407 shares acquired at $0.00 and 407 shares disposed at $0.00 (same-day acquisition and disposition).
• Shares owned after the transactions: Not specified in the information provided in this summary.
• Footnotes from the filing:
  • F1: Shares were acquired on vesting of restricted stock units.
  • F2: Each RSU represents a contingent right to receive one share of Bio‑Rad Class A common stock.
  • F3: The RSUs vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.

Context

• The RSU entry (A) is a grant vesting event — a form of compensation, not an open‑market purchase.
• The M entries show a same‑day acquisition and disposal of 407 derivative shares; when acquisition and disposal happen the same day it commonly reflects an immediate sale or net settlement (cashless exercise), though the filing itself does not state the method.
• These transactions are routine insider equity events (vesting and derivative conversion) and should not be interpreted as explicit buy or sell signals by themselves.